CH BAYONNE Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2009
NCT02302469
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

Centre Hospitalier de BAYONNE | Clinic Delay, Bayonne, France

Active Ingredients

Drugs in Phase 3 Trials (2)

bortezomib (velcade) (1 trial)

melphalan (alkeran) (1 trial)

Drugs in Phase 2 Trials (1)

lenalidomide (revlimid) (1 trial)

Drugs in Other Trials (3)

hepatitis b vaccine (recombinant) (recombivax) (1 trial)

polymethylmetacrylate (1 trial)

polysulfone (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Myeloma (Phase 3)

Neoplasms, Plasma Cell (Phase 3)

Waldenstrom Macroglobulinemia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 6